The BPC-157 papers and regulatory documents
The human reports are a small part of this list. Their size matters more than the length of the bibliography.
Different documents, different jobs
The knee-pain case series, bladder pilot and intravenous safety pilot are the human reports. The 2025 musculoskeletal review puts that small record beside the much larger preclinical literature.
The animal and cell papers concern tendon healing, gastric ulcers, vascular signaling, pharmacokinetics, distant-organ injury and serotonin or growth-hormone-receptor activity. Their findings remain attached to those settings.
The FDA documents concern U.S. legal status and compounding. They are records of regulatory requirements and proceedings rather than clinical trials. The length of a bibliography matters little to me if its documents answer different questions.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
- Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
- Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (public calendar listing BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List). ↗
- FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (entries for 'BPC-157 (free base)' and 'BPC-157 acetate' under nominated but withdrawn substances, with FDA's safety concerns retained). ↗
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; the 503A/503B compounding framework; the January 7, 2025 revised interim policy). ↗
- Author group (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18:1450. ↗
- Tohyama Y, et al.. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004;76:345-357. ↗
- Boban Blagaic A, et al.. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512:173-179. ↗
- Chang CH, et al.. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-19077. ↗